Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Gene Therapy Drug May Show Promise In Treatment Of Huntington’s Disease

XTALKS VITALS NEWS

Wal-Mart

A novel gene therapy drug developed by antibody company Vybion, has been shown to block cellular gene dysregulation and delay cognitive and motor problems associated with Huntington’s disease.

Tweetables from this article:

Tweet: The drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease http://ctt.ec/d9KhBThe drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease.

Share this!

September 1, 2016 | by Sarah Massey, M.Sc.

A novel gene therapy drug developed by antibody company Vybion has been shown to block cellular gene dysregulation and delay cognitive and motor problems associated with Huntington’s disease. The details of the intrabody drug INT41, an antibody that binds to an intracellular protein, were published in the Journal of Neurodegenerative Diseases.

INT41 prevents toxic N-terminal huntingtin fragments from being transported into the nucleus of the cell and blocks them from binding with the DNA. The drug was tested in the well-validated R6/2 mouse model of Huntington’s disease.

“We believe that our therapeutic approach to the treatment of Huntington's disease has provided a biological rationale linking Huntington's disease progression and toxic N-terminal fragments,” said Dr. Lee Henderson, CEO of Vybion. “We look forward to completing our plans for human patient trials.”

The drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease. Vybion’s proprietary technologies revolve around the discovery and development of intrabody drugs for multiple neurodegenerative diseases.

“The data also demonstrate that Vybion's platform may have broader application in generating intrabody drug candidates to difficult-to-drug targets, including intracellular proteins in neurodegenerative disorders and other disease areas such as oncology,” said a statement released by Vybion. “Further, the platform may be used to validate new targets of interest, particularly in intracellular signal transduction pathways, prior to generation of new therapeutic candidates.”


Keywords: Gene Therapy, Huntington's Disease, Drug Development


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.